News

Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

West Pharmaceutical Services (WST) has drawn fresh investor attention after reporting second quarter results that exceeded expectations and raising full year revenue and adjusted earnings guidance, supported by demand for biologics and biosimilars related products. See our latest analysis for West Pharmaceutical Services. The share price has been volatile in recent months, with a 13.4% 90 day share price return and 23.4% year to date share price return, but a 6.6% decline over 30 days as...

West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the compan

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.

Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.

TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.

STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.

IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.

West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C

Moby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call

West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.

WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.

While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

West Pharmaceutical (WST) delivered earnings and revenue surprises of +13.94% and +4.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share

Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect.

WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.

OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.

ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.

ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.

The companies you own inside this consumer staples fund are collectively signaling stronger profits are on the way.

DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.

West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.